| pubmed-article:3288124 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3288124 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:3288124 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:3288124 | lifeskim:mentions | umls-concept:C0025202 | lld:lifeskim |
| pubmed-article:3288124 | lifeskim:mentions | umls-concept:C0005953 | lld:lifeskim |
| pubmed-article:3288124 | lifeskim:mentions | umls-concept:C0002073 | lld:lifeskim |
| pubmed-article:3288124 | lifeskim:mentions | umls-concept:C0439859 | lld:lifeskim |
| pubmed-article:3288124 | lifeskim:mentions | umls-concept:C1317973 | lld:lifeskim |
| pubmed-article:3288124 | lifeskim:mentions | umls-concept:C0183683 | lld:lifeskim |
| pubmed-article:3288124 | lifeskim:mentions | umls-concept:C0344211 | lld:lifeskim |
| pubmed-article:3288124 | lifeskim:mentions | umls-concept:C1521721 | lld:lifeskim |
| pubmed-article:3288124 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:3288124 | lifeskim:mentions | umls-concept:C1171411 | lld:lifeskim |
| pubmed-article:3288124 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:3288124 | pubmed:dateCreated | 1988-6-24 | lld:pubmed |
| pubmed-article:3288124 | pubmed:abstractText | Nineteen patients with metastatic malignant melanoma were treated with 20 courses of high-dose combination alkylating agent chemotherapy and autologous bone marrow support. All 20 treatment courses were evaluable for toxic reactions and 17 of 20 courses were assessable for response. Twelve of the 20 courses were given at the phase 2 dose per square meter of cyclophosphamide (5.625 g), cisplatin (165 mg), and carmustine (600 mg). Marrow reconstitution occurred with a median time to recovery of 21 and 24 days for more than 500 neutrophils and more than 20,000 platelets, respectively. The overall response rate was 65%, with one patient achieving a complete response with chemotherapy alone. Ten additional patients achieved partial responses following chemotherapy, of which three were subsequently rendered disease free by surgical resection of single areas of residual tumor. Two of these patients are alive and disease free more than 22 months following chemotherapy and one remains relapse free. The median survival for responding patients was 15.2 months and 8.6 months for the entire group. | lld:pubmed |
| pubmed-article:3288124 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3288124 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3288124 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3288124 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3288124 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:3288124 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3288124 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3288124 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3288124 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3288124 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3288124 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:3288124 | pubmed:issn | 0003-987X | lld:pubmed |
| pubmed-article:3288124 | pubmed:author | pubmed-author:FreiEE3rd | lld:pubmed |
| pubmed-article:3288124 | pubmed:author | pubmed-author:EliasAA | lld:pubmed |
| pubmed-article:3288124 | pubmed:author | pubmed-author:PetersW PWP | lld:pubmed |
| pubmed-article:3288124 | pubmed:author | pubmed-author:SchnipperL... | lld:pubmed |
| pubmed-article:3288124 | pubmed:author | pubmed-author:AntmanK HKH | lld:pubmed |
| pubmed-article:3288124 | pubmed:author | pubmed-author:SchoenfeldD... | lld:pubmed |
| pubmed-article:3288124 | pubmed:author | pubmed-author:SheaT CTC | lld:pubmed |
| pubmed-article:3288124 | pubmed:author | pubmed-author:HennerW DWD | lld:pubmed |
| pubmed-article:3288124 | pubmed:author | pubmed-author:EderJ PJP | lld:pubmed |
| pubmed-article:3288124 | pubmed:author | pubmed-author:SchryberSS | lld:pubmed |
| pubmed-article:3288124 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3288124 | pubmed:volume | 124 | lld:pubmed |
| pubmed-article:3288124 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3288124 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3288124 | pubmed:pagination | 878-84 | lld:pubmed |
| pubmed-article:3288124 | pubmed:dateRevised | 2008-3-17 | lld:pubmed |
| pubmed-article:3288124 | pubmed:meshHeading | pubmed-meshheading:3288124-... | lld:pubmed |
| pubmed-article:3288124 | pubmed:meshHeading | pubmed-meshheading:3288124-... | lld:pubmed |
| pubmed-article:3288124 | pubmed:meshHeading | pubmed-meshheading:3288124-... | lld:pubmed |
| pubmed-article:3288124 | pubmed:meshHeading | pubmed-meshheading:3288124-... | lld:pubmed |
| pubmed-article:3288124 | pubmed:meshHeading | pubmed-meshheading:3288124-... | lld:pubmed |
| pubmed-article:3288124 | pubmed:meshHeading | pubmed-meshheading:3288124-... | lld:pubmed |
| pubmed-article:3288124 | pubmed:meshHeading | pubmed-meshheading:3288124-... | lld:pubmed |
| pubmed-article:3288124 | pubmed:meshHeading | pubmed-meshheading:3288124-... | lld:pubmed |
| pubmed-article:3288124 | pubmed:meshHeading | pubmed-meshheading:3288124-... | lld:pubmed |
| pubmed-article:3288124 | pubmed:meshHeading | pubmed-meshheading:3288124-... | lld:pubmed |
| pubmed-article:3288124 | pubmed:meshHeading | pubmed-meshheading:3288124-... | lld:pubmed |
| pubmed-article:3288124 | pubmed:meshHeading | pubmed-meshheading:3288124-... | lld:pubmed |
| pubmed-article:3288124 | pubmed:meshHeading | pubmed-meshheading:3288124-... | lld:pubmed |
| pubmed-article:3288124 | pubmed:meshHeading | pubmed-meshheading:3288124-... | lld:pubmed |
| pubmed-article:3288124 | pubmed:meshHeading | pubmed-meshheading:3288124-... | lld:pubmed |
| pubmed-article:3288124 | pubmed:meshHeading | pubmed-meshheading:3288124-... | lld:pubmed |
| pubmed-article:3288124 | pubmed:meshHeading | pubmed-meshheading:3288124-... | lld:pubmed |
| pubmed-article:3288124 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:3288124 | pubmed:articleTitle | Malignant melanoma. Treatment with high-dose combination alkylating agent chemotherapy and autologous bone marrow support. | lld:pubmed |
| pubmed-article:3288124 | pubmed:affiliation | Department of Medicine, Dana-Farber Cancer Institute, Boston. | lld:pubmed |
| pubmed-article:3288124 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3288124 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:3288124 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
